MOUNTAIN VIEW, CA , Sept. 24, 2018 (GLOBE NEWSWIRE) — Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds, provided an update on the company’s sirolimus-eluting bioresorbable scaffold (BRS) products at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting during the following sessions: Didactic Session: Drug-Eluting Stents, Bioresorbable Scaffolds, and Coronary […]
Coronary/Structural Heart
Data Presented at TCT 2018 Shows Use of Impella and Best Practices Increases Cardiogenic Shock Survival
SAN DIEGO, Sept. 24, 2018 (GLOBE NEWSWIRE) — A new analysis of data from Abiomed’s (NASDAQ:ABMD) Impella® Quality (IQ) Database shows a relative increase of 24% in mean survival in acute myocardial infarction (AMI) cardiogenic shock patients since Impella’s cardiogenic shock FDA post-market approval. Part of the reason for the increase was a […]
Medtronic Builds on TAVR Clinical Evidence Portfolio with Five-Year CoreValve Durability Data and Complete Two-Year Outcomes in Intermediate Risk Aortic Stenosis Patients
DUBLIN and SAN DIEGO – September 24, 2018 – Medtronic plc (NYSE:MDT), a global leader in heart valve therapies, today announced new data presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation. Over the weekend, investigators presented the longest-term data to-date from […]
TCT Congress 2018: BIOTRONIK’s Orsiro Ultrathin Drug-Eluting Stent Further Outperforms Xience at Two-Year Follow-Up
SAN DIEGO and BUELACH, Switzerland, Sept. 24, 2018 /PRNewswire/ — Today, BIOTRONIK announced two-year data from the BIOFLOW-V randomized trial comparing the Orsiroa and Xienceb drug-eluting stents (DES). The data shows statistically improved outcomes for patients treated with Orsiro across a range of clinical endpoints including 24-month target lesion failure (TLF). This pivotal US investigational device exemption trial included […]
Cardiac Dimensions Announces Positive Late-Breaking Results for Blinded Clinical Trial of Minimally Invasive Heart Failure Treatment
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, announced results of the company’s landmark REDUCE FMR clinical trial, which were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Diego. The study met […]
Landmark Study Shows Treatment with Abbott’s MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation
SAN DIEGO, Sept. 23, 2018 /PRNewswire/ — Abbott (NYSE :ABT ) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip® device to guideline-directed medical therapy in select patients with secondary (or functional) mitral regurgitation, or a leaky heart valve, as a result of advanced heart failure. The landmark […]
Corindus Announces First Live Transmission of Remote Robotic Demonstration Performed at Transcatheter Cardiovascular Therapeutics 2018 Conference
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced the first live transmission of a remote interventional procedure using the company’s CorPath® platform was performed at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Diego, CA on September 22, 2018. The remote interventional […]
Abiomed to Showcase Expanded FDA Indications and Next Generation Heart Recovery Products at TCT 2018
DANVERS, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), the leader in heart recovery, announces its initiatives at the 30th Transcatheter Cardiovascular Therapeutics (TCT) conference will highlight the recently expanded FDA indications for high-risk PCI and cardiogenic shock. Initiatives will also highlight Protected PCI’s ability to allow for […]
Cardiac Dimensions Announces the Randomization of its First Patient in the U.S. Pivotal Trial – The CARILLON Trial
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the company has randomized its first patient in the CARILLON Pivotal Trial. The CARILLON Trial is evaluating the Carillon® Mitral Contour System®for the treatment of functional […]
LUMEDX Rolls Out Comprehensive Cardiovascular Information System at Major Academic Medical Center
OAKLAND, Calif.–(BUSINESS WIRE)–LUMEDX Corporation, a provider of wholly integrated cardiovascular data intelligence and imaging solutions, announced today that it is working with Duke Health to implement a comprehensive cardiovascular information system (CVIS) for Duke’s non-invasive cardiac labs. The implementation marks the third phase of a larger Duke-LUMEDX CVIS project, which […]



